×
S&P 500   3,751.52 (-1.93%)
DOW   30,432.92 (-2.14%)
QQQ   279.58 (-0.90%)
AAPL   138.66 (-0.19%)
MSFT   256.65 (-1.13%)
META   161.22 (+0.74%)
GOOGL   2,165.24 (-0.44%)
AMZN   110.43 (+0.79%)
TSLA   665.23 (-2.43%)
NVDA   145.84 (+0.42%)
NIO   21.54 (+0.84%)
BABA   115.36 (-0.55%)
AMD   73.55 (-0.16%)
MU   54.97 (+2.46%)
CGC   2.66 (-5.34%)
T   20.94 (-1.74%)
GE   60.83 (-4.27%)
F   10.90 (-3.71%)
DIS   94.10 (-2.12%)
AMC   12.94 (-4.36%)
PFE   50.60 (-3.27%)
PYPL   72.00 (+0.84%)
NFLX   178.84 (-0.62%)
S&P 500   3,751.52 (-1.93%)
DOW   30,432.92 (-2.14%)
QQQ   279.58 (-0.90%)
AAPL   138.66 (-0.19%)
MSFT   256.65 (-1.13%)
META   161.22 (+0.74%)
GOOGL   2,165.24 (-0.44%)
AMZN   110.43 (+0.79%)
TSLA   665.23 (-2.43%)
NVDA   145.84 (+0.42%)
NIO   21.54 (+0.84%)
BABA   115.36 (-0.55%)
AMD   73.55 (-0.16%)
MU   54.97 (+2.46%)
CGC   2.66 (-5.34%)
T   20.94 (-1.74%)
GE   60.83 (-4.27%)
F   10.90 (-3.71%)
DIS   94.10 (-2.12%)
AMC   12.94 (-4.36%)
PFE   50.60 (-3.27%)
PYPL   72.00 (+0.84%)
NFLX   178.84 (-0.62%)
S&P 500   3,751.52 (-1.93%)
DOW   30,432.92 (-2.14%)
QQQ   279.58 (-0.90%)
AAPL   138.66 (-0.19%)
MSFT   256.65 (-1.13%)
META   161.22 (+0.74%)
GOOGL   2,165.24 (-0.44%)
AMZN   110.43 (+0.79%)
TSLA   665.23 (-2.43%)
NVDA   145.84 (+0.42%)
NIO   21.54 (+0.84%)
BABA   115.36 (-0.55%)
AMD   73.55 (-0.16%)
MU   54.97 (+2.46%)
CGC   2.66 (-5.34%)
T   20.94 (-1.74%)
GE   60.83 (-4.27%)
F   10.90 (-3.71%)
DIS   94.10 (-2.12%)
AMC   12.94 (-4.36%)
PFE   50.60 (-3.27%)
PYPL   72.00 (+0.84%)
NFLX   178.84 (-0.62%)
S&P 500   3,751.52 (-1.93%)
DOW   30,432.92 (-2.14%)
QQQ   279.58 (-0.90%)
AAPL   138.66 (-0.19%)
MSFT   256.65 (-1.13%)
META   161.22 (+0.74%)
GOOGL   2,165.24 (-0.44%)
AMZN   110.43 (+0.79%)
TSLA   665.23 (-2.43%)
NVDA   145.84 (+0.42%)
NIO   21.54 (+0.84%)
BABA   115.36 (-0.55%)
AMD   73.55 (-0.16%)
MU   54.97 (+2.46%)
CGC   2.66 (-5.34%)
T   20.94 (-1.74%)
GE   60.83 (-4.27%)
F   10.90 (-3.71%)
DIS   94.10 (-2.12%)
AMC   12.94 (-4.36%)
PFE   50.60 (-3.27%)
PYPL   72.00 (+0.84%)
NFLX   178.84 (-0.62%)
NYSE:GBS

GBS Stock Forecast, Price & News

$0.66
0.00 (-0.30%)
(As of 07/1/2022 09:48 AM ET)
Add
Compare
Today's Range
$0.66
$0.67
50-Day Range
$0.56
$0.79
52-Week Range
$0.38
$5.11
Volume
100 shs
Average Volume
87,341 shs
Market Capitalization
$9.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

GBS MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$12,992 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.63) to ($0.31) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

0.55 out of 5 stars

30 days | 90 days | 365 days | Advanced Chart

Receive GBS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GBS and its competitors with MarketBeat's FREE daily newsletter.

GBS logo

About GBS (NYSE:GBS) Stock

GBS Inc. operates as a biosensor diagnostic technology company. It offers Saliva Glucose Biosensor that uses saliva to measure glucose non-invasively. The company also focuses on developing COV2 test, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumour markers, hormones, and nucleic acid diagnostic modalities. It has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was incorporated in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.

GBS Stock News Headlines

GBS: GBS’ Prints Are All Over It
See More Headlines

Industry, Sector and Symbol

Industry
N/A
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
7
Year Founded
N/A

Company Calendar

Last Earnings
5/10/2022
Today
7/05/2022
Fiscal Year End
6/30/2023

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.98 million

Miscellaneous

Free Float
14,850,000
Market Cap
$9.83 million
Optionable
Not Optionable
Beta
0.91














GBS Frequently Asked Questions

How has GBS's stock price performed in 2022?

GBS's stock was trading at $1.4350 on January 1st, 2022. Since then, GBS shares have decreased by 54.0% and is now trading at $0.66.
View the best growth stocks for 2022 here
.

How were GBS's earnings last quarter?

GBS Inc. (NYSE:GBS) announced its quarterly earnings results on Tuesday, May, 10th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.07. The firm had revenue of $0.19 million for the quarter.
View GBS's earnings history
.

Who are GBS's key executives?

GBS's management team includes the following people:
  • Dr. Stephen Constantine Boyages M.D., MBBS, Ph.D., Interim CEO & Chairman (Age 64, Pay $20.51k)
  • Mr. Spiro Kevin Sakiris B.Bus, C.A., CA, Dip Law, Chief Financial Officer (Age 60, Pay $265.58k) (LinkedIn Profile)
  • Mr. Harry Simeonidis, Pres of Asia Pacific - Sales & Marketing (Age 54, Pay $350.69k)
  • Ms. Victoria Gavrilenko, Operations Mang. (Age 39)
  • Mr. Alex Arzeno, VP of Investor Relations

What is GBS's stock symbol?

GBS trades on the New York Stock Exchange (NYSE) under the ticker symbol "GBS."

How do I buy shares of GBS?

Shares of GBS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is GBS's stock price today?

One share of GBS stock can currently be purchased for approximately $0.66.

How much money does GBS make?

GBS (NYSE:GBS) has a market capitalization of $9.83 million and generates $1.98 million in revenue each year.

How many employees does GBS have?

GBS employs 7 workers across the globe.

How can I contact GBS?

The official website for GBS is www.gbs.inc. The company can be reached via phone at 646 828 8258.

This page (NYSE:GBS) was last updated on 7/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.